Search

Your search keyword '"Yerly S"' showing total 713 results

Search Constraints

Start Over You searched for: Author "Yerly S" Remove constraint Author: "Yerly S"
713 results on '"Yerly S"'

Search Results

2. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

3. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study

4. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods

5. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

6. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.

7. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

8. High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

9. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

11. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

12. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

14. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study

15. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

16. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods

17. Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study

18. Mining for pairs: shared clinic visit dates identify steady HIV‐positive partnerships

19. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

20. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study

21. Transient elevation of humoral responses against apolipoprotein A-1 following COVID-19 and its association with symptoms persistence

22. Ethnicity predicts viral rebound after travel to the tropics in HIV‐infected travelers to the tropics in the Swiss HIV Cohort Study

24. Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017

25. High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

26. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study

27. A highly virulent variant of HIV-1 circulating in the Netherlands

28. Children living with HIV in Europe: do migrants have worse treatment outcomes?

29. Similar but different: integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics

30. Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study

31. Malignancies among children and young people with HIV in Western and Eastern Europe and Thailand the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) study group

32. Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study

33. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals

34. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

35. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study

36. Sars-CoV2- infection as a trigger of humoral response against apolipoprotein A-1

37. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

39. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

40. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

41. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection

42. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

43. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals

44. Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission

45. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001–2011

47. Ageing with HIV: medication use and risk for potential drug–drug interactions

50. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand

Catalog

Books, media, physical & digital resources